<DOC>
	<DOCNO>NCT00463554</DOCNO>
	<brief_summary>The primary objective study obtain clinical performance information GYNECARE TVT-SECUR* System ( Tension-free Support Incontinence ) woman stress urinary incontinence ( SUI ) .</brief_summary>
	<brief_title>TVT-SECUR A Pilot Study Treatment Stress Urinary Incontinence</brief_title>
	<detailed_description>The primary variable effectiveness &gt; 50 % improvement subjective symptom Visual Analog Scale ( VAS ) Visit 3/Week 5 ( 35 day post-surgery ) accept .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Must female objective , demonstratable sign SUI stress predominant mixed incontinence require elective , primary surgical intervention . Must least 21 year old . Must postmenopausal ( amenorrhea ) least 1 year surgically sterile ( bilateral salpingooophorectomy tubal ligation otherwise incapable pregnancy ) negative pregnancy test prior study entry decide cease childbearing . Agrees participate study , include study related procedure evaluation document agreement sign IRB/ECapproved informed consent Have coexistent pathology require concomitant surgery may impact procedure i.e . surgery involve anterior vaginal wall ( e.g . anterior colporrhaphy , diverticulum , anterior Prolift ) Any allowable concomitant surgery must perform prior GYNECARE TVT SECUR System surgery . Have intrinsic sphincter deficiency ( ISD ) [ Urethral Pressure Profile ( UPP ) maximum urethral closing pressure ( MUCP ) &lt; 20cm H2O Leak Point Pressure ( LPP ) &lt; 60 ] . Have active urinary tract infection ( UTI ) vaginal infection time surgery . Have fix urethra ( &lt; 30Â° mobility QTip Straining Test ) . Have prior incontinence surgery . Have postvoid residual volume &gt; 100mL . Have coexistent pelvic organ prolapse symptomatic extend beyond hymen . Have low urinary tract pathology form fistula diverticulum . Have malignancy history malignancy within past 5 year , except basal cell carcinoma treat local excision longer present . Are anticoagulant therapy . Have receive experimental drug use experimental medical device within 30 day prior planned start treatment . Are deemed investigator medically unfit surgery opinion investigator enrol study precaution , warning contraindication outline GYNECARE TVT SECUR System IFU . Employees investigator study center direct involvement propose study study direction investigator study center .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Incontinence</keyword>
	<keyword>Stress Urinary</keyword>
</DOC>